Related Experiment Video
Updated: Oct 12, 2025

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Disparities in Hepatocellular Carcinoma Survival by Insurance Status: A Population-Based Study in China
Jing Wu1,2, Chengyu Liu1,2, Fengmei Wang3
1School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China.
Insights
Hepatocellular carcinoma (HCC) patients with Urban and Rural Resident Basic Medical Insurance (URRBMI) in China face significantly worse survival rates compared to those with Urban Employee Basic Medical Insurance (UEBMI). This highlights critical healthcare disparities in HCC treatment outcomes.
Area of Science:
- Oncology
- Health Services Research
- Public Health
Background:
- Health disparities in basic medical insurance coverage for hepatocellular carcinoma (HCC) patients in China remain under-examined.
- Understanding survival differences based on insurance type is crucial for addressing inequities in cancer care.
Purpose of the Study:
- To investigate survival disparities among hepatocellular carcinoma (HCC) patients based on their basic medical insurance status in Tianjin, China.
- To compare outcomes between Urban Employee Basic Medical Insurance (UEBMI) and Urban and Rural Resident Basic Medical Insurance (URRBMI) enrollees.
Main Methods:
- Retrospective analysis of the Tianjin Basic Medical Insurance claims database (2011-2017).
- Kaplan-Meier and parametric models assessed overall survival; Cox proportional hazards models adjusted for confounders.
- Propensity score matching was used for sensitivity analysis.
Main Results:
- The study included 2,068 HCC patients (1,468 UEBMI, 570 URRBMI).
- Patients with URRBMI had a median survival of 12.2 months versus 37.8 months for UEBMI.
- URRBMI patients faced a 72% higher risk of death (adjusted HR: 1.72) compared to UEBMI patients.
Conclusions:
- Hepatocellular carcinoma (HCC) patients insured under URRBMI exhibit significantly poorer survival outcomes than those under UEBMI.
- These findings underscore the existence of healthcare disparities linked to basic medical insurance types in China.
- Further research is needed to elucidate and address these inequities in cancer patient care.
Abstract:
Objective: Health disparities related to basic medical insurance in China have not been sufficiently examined, particularly among patients with hepatocellular carcinoma (HCC). This study aims to investigate the disparities in HCC survival by insurance status in Tianjin, China. Methods: This retrospective analysis used data from the Tianjin Basic Medical Insurance claims database, which consists of enrollees covered by Urban Employee Basic Medical Insurance (UEBMI) and Urban and Rural Resident Basic Medical Insurance (URRBMI). Adult patients newly diagnosed with HCC between 2011 and 2016 were identified and followed until death from any cause, withdrawal from UEBMI or URRBMI, or the latest data in the dataset (censoring as of December 31st 2017), whichever occurred first. Patients' overall survival during the follow-up was assessed using Kaplan-Meier and extrapolated by six parametric models. The hazard ratio (HR) and 95% confidence intervals (CI) were calculated with the adjusted Cox proportional hazards model including age at diagnosis, sex, baseline comorbidities and complications, baseline healthcare resources utilization and medical costs, tumor metastasis at diagnosis, the initial treatment after diagnosis and antiviral therapy during the follow-up. Results: Two thousand sixty eight patients covered by UEBMI (N = 1,468) and URRBMI (N = 570) were included (mean age: 60.6 vs. 60.9, p = 0.667; female: 31.8 vs. 27.7%, p = 0.074). The median survival time for patients within the UEBMI and URRBMI were 37.8 and 12.2 months, and the 1-, 3-, 5-, 10-year overall survival rates were 63.8, 50.2, 51.0, 33.4, and 44.4, 22.8, 31.5, 13.1%, respectively. Compared with UEBMI, patients covered by URRBMI had 72% (HR: 1.72; 95% CI: 1.47-2.00) higher risk of death after adjustments for measured confounders above. The survival difference was still statistically significant (HR: 1.49; 95% CI: 1.21-1.83) in sensitivity analysis based on propensity score matching. Conclusions: This study reveals that HCC patients covered by URRBMI may have worse survival than patients covered by UEBMI. Further efforts are warranted to understand healthcare disparities for patients covered by different basic medical insurance in China.
More Related Videos
Related Concept Videos
Cancer Survival Analysis
Comparing the Survival Analysis of Two or More Groups
Targeted Cancer Therapies
There are several types of targeted therapies against...

